Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares Outstanding
Ratios

Acro Biomedical (ACBM) Receivables - Net (2021 - 2023)

Acro Biomedical has reported Receivables - Net over the past 3 years, most recently at $498500.0 for Q2 2023.

  • Quarterly results put Receivables - Net at $498500.0 for Q2 2023, up 67.0% from a year ago — trailing twelve months through Jun 2023 was $498500.0 (up 67.0% YoY), and the annual figure for FY2022 was $638500.0, up 6.77%.
  • Receivables - Net for Q2 2023 was $498500.0 at Acro Biomedical, down from $608500.0 in the prior quarter.
  • Over the last five years, Receivables - Net for ACBM hit a ceiling of $638500.0 in Q4 2022 and a floor of $278500.0 in Q3 2022.
  • Median Receivables - Net over the past 3 years was $498500.0 (2023), compared with a mean of $459857.1.
  • Biggest five-year swings in Receivables - Net: increased 6.77% in 2022 and later skyrocketed 103.85% in 2023.
  • Acro Biomedical's Receivables - Net stood at $598000.0 in 2021, then increased by 6.77% to $638500.0 in 2022, then fell by 21.93% to $498500.0 in 2023.
  • The last three reported values for Receivables - Net were $498500.0 (Q2 2023), $608500.0 (Q1 2023), and $638500.0 (Q4 2022) per Business Quant data.